Renal antifibrotic effect of n-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats

American Journal of Nephrology

Volumn 37, Issue 1, 2013, Pages 65-73

  Castoldi, G ^a   Di Gioia, C R T ^b   Bombardi, C ^a   Preziuso, C ^b   Leopizzi, M ^b   Maestroni, S ^c   Corradi, B ^a   Zerbini, G ^c   Stella, A ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Diabetic nephropathy; Experimental models; Fibrosis; N acetyl seryl aspartyl lysyl proline; Rats

Indexed keywords

ALBUMIN; BUFFER; GLUCOSE; NEPHRIN; RAMIPRIL; SERASPENIDE; SODIUM CHLORIDE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; KIDNEY FIBROSIS; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; GLOMERULAR FILTRATION RATE; GROWTH INHIBITORS; KIDNEY GLOMERULUS; MALE; MEMBRANE PROTEINS; NEPHROSCLEROSIS; OLIGOPEPTIDES; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84872272401     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346116     Document Type: Article

References (25)

1. American Diabetes Association: Standards of medical care in diabetes: 2011. Diabetes Care 2011; 34(suppl 1):S11-S61
2. UKPDS Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853
3. UKPDS Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
4. Hagiwara S, Kantharidis P, Cooper ME: What are new avenues for renal protection, in addition to RAAS inhibition? Curr Hypertens Rep 2012; 14: 100-110
5. Heerspink HJ, de Zeeuw D: The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011; 8: 392-402
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension: 2007 ESH-ESC practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762
7. Siragy HM, Carey RM: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010; 31: 541-550
8. Carretero OA: Novel mechanism of action of ACE and its inhibitors. Am J Physiol Heart Circ Physiol 2005; 289:H1796-H1797
9. Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A, Frindel E: Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 1990; 170: 986-993
10. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M: Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp- Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 1993; 82: 3307-3314
11. Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet JM, Lenfant M, Corvol P, Ménard J : Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetylseryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844
12. Shibuya K, Kanasaki K, Isono M, Sato H, Omata M, Sugimoto T, Araki S-I, Isshiki K, Kashiwagi A, Haneda M, Koya D: N-acetylseryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005; 54: 838-845
13. Wang M, Liu R, Jia X, Mu S, Xie R: N-acetylseryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int J Mol Med 2010; 26: 795-801
14. Omata M, Taniguchi H, Koya D, Kanasaki K, Sho R, Kato Y, Kojima R, Haneda M, Inomata N: N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol 2006; 17: 674-685
15. Liao TD, Yang XP, D'Ambrosio M, Zhang Y, Rhaleb NE, Carretero OA: N-acetyl-serylaspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension 2010; 55: 459-467
16. Rhaleb NE, Pokharel S, Sharma U, Carretero OA: Renal protective effects of N-acetyl-seryl-aspartyl-lysyl-proline in DOCA-salt hypertensive mice. J Hypertens 2011; 29: 330-338
17. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M: N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 2003; 14: 863-872
18. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE: Angiotensin converting enzyme inhibitors. A new mechanism of action. Circulation 2005; 112: 2436-2445
19. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE: Antifibrotic effect of Ac-SDKP and angiotensin- converting enzyme inhibition in hypertension. J Hypertens 2004; 22: 593-603
20. Lin C-X, Rhaleb N-E, Yang X-P, Liao T-D, D'Ambrosio MA, Carretero AO: Prevention of aortic fibrosis by N-acetyl-seryl-aspartyllysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2008; 295:H1253-H1261
21. Yang F, Yang X-P, Liu YH, Xu J, Cingolani O, Rhaleb NE, Carretero OA: Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43: 229-236
22. Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb NE: Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 2003; 42: 1164-1170
23. Castoldi G, di Gioia CR, Bombardi C, Perego C, Perego L, Mancini M, Leopizzi M, Corradi B, Perlini S, Zerbini G, Stella A: Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci 2010; 118: 211-220
24. Infanger M, Grosse J, Westphal K, Leder A, Ulbrich C, Paul M, Grimm D: Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann Vasc Surg 2008; 22: 273-284
25. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001; 37: 1262-1267.